JumpCode provides technology for depleting unwanted nucleic acid. The CRISPRclean is a proprietary technology that utilizes the CRISPR/CAS system to deplete unwanted nucleic acid molecules from sequencing libraries. The applications of the technology include host organism depletion, ribosomal RNA depletion, repetitive sequence depletion, allele-specific depletion, and others. The patented CRISPRclean technology allows the researcher to remove unwanted regions. The company was founded in 2016 and headquartered in Carlsbad, United States. It has raised $38.7M in series b funding, with backing from Baird Capital, Arboretum Ventures, LYZZ Capital, HHS. The company operates in the Life Sciences - Genomics, Life Sciences - Life Sciences Platforms and Tools, HealthTech - Life Sciences Tech space. Provider of a technology for depleting unwanted nucleic acid.
JUMPCODE Genomics
Series BJumpCode provides technology for depleting unwanted nucleic acid. The CRISPRclean is a proprietary technology that utilizes the CRISPR/CAS system to deplete unwanted nucleic acid molecules from sequencing libraries. The applications of the technology include host organism depletion, ribosomal RNA depletion, repetitive sequence depletion, allele-specific depletion, and others. The patented CRISPRclean technology…
About
Business model
Life Sciences Tech > Research & Development > Drug Informatics > Scientific Literature > Data Mining > Gene Analysis,
Genomics > Enabling Technologies > Kits and Reagents > Detection and Quantification,
Life Sciences Platforms and Tools > Research Reagents and Kits > Genomics > Nucleic Acid Synthesis > DNA
Institutional investors
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.